Fundraising FoxSwan Venture Fund — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
Opticyte develops the VitalO₂, a preclinical-stage medical device aimed at hospitals, with an FDA De Novo pathway and Breakthrough Device Designation.
BiotechHealthtechMedical DevicesSeattle, US
Lori Arakaki(Founder)inRobert Masterson(Executive Officer, Director, Promoter)Kenneth Schenkman(Executive Officer, Director, Promoter)Lorilee Arakaki(Executive Officer, Director, Promoter)
Seattle, US
Gilad Berenstein(Executive Officer, Director, Promoter)
BoardAviv Shahar(Director)Yair Berenstein(Director)Court Lorenzini(Director)Edan Shahar(Director)
Co-investorsSeaChangeAlliance of AngelsBay Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.